Sign in
Active, not recruitingPhase 4

Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia

Key facts

Who runs it
Jinnah Postgraduate Medical Centre
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
122 people, planned
Started
21 Sept 2024
Ended
21 Mar 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Oxcarbazepine
  • Carbamazepine
Record updated
4 March 2025

Who can take part

Age
25 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients of either gender (male or female)
  • Patients of age 25-80 years
  • Patients presenting with trigeminal neuralgia of any frequency and severity (according to operational definition) for six months
  • Patients not already receiving carbamazepine or oxcarbazepine for the management of trigeminal neuralgia

Who cannot take part

  • Patients who have undergone any surgical procedure for the treatment of trigeminal neuralgia
  • Patients not already receiving carbamazepine or oxcarbazepine for the management of trigeminal neuralgia
  • Patients with renal and hepatic issue such as chronic renal failure and chronic liver disease
  • Patients with seizures
  • Patients who are intolerant to and allergic to both treatment drugs (oxcarbazepine and carbamazepine)
  • Pregnant and Iactating mothers
  • Patients who are not willing to participate in the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Trigeminal neuralgia is a debilitating neurological condition, affecting quality of life in most affected patients. Carbamazepine has traditionally been used for the management of this condition, but it has a moderate effectiveness and a poor side-effect profile. Oxcarbazepine is more tolerable, and has a more favorable side-effect profile. This study aims to compare the effectiveness of oxcarbazepine and carbamazepine in the management of this condition, for improved prescription practices in the future.

The 2 groups in the trial

  • Oxcarbazepine (Group A)Treatment being tested

    Starting dose of oxcarbazepine 150 mg BD, titrated up if no pain relief

    Treatment: Oxcarbazepine

  • Carbamazepine (Group B)Existing treatment, for comparison

    Starting dose of carbamazepine 100 mg BD, titrated up if no relief

    Treatment: Carbamazepine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia in Patients Presenting in Outpatient Department of Neurology in Jinnah Postgraduate Medical Centre
Record updated
4 March 2025